Glassman Wealth Services Editas Medicine, Inc. Transaction History

Glassman Wealth Services

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.92 - $9.31 $48 - $65	-7 Reduced 24.14%	22 $0
Q2 2023 Aug 08, 2023	BUY	$6.36 - $11.47 $184 - $332	29 New	29 $0
Q1 2022 Apr 14, 2022	SELL	$14.08 - $27.63 $605 - $1,188	-43 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $9,743 - $14,889	-367 Reduced 89.51%	43 $1,000
Q3 2021 Nov 10, 2021	BUY	$39.27 - $72.94 $1,217 - $2,261	31 Added 8.18%	410 $17,000
Q2 2021 Aug 04, 2021	SELL	$31.29 - $56.64 $4,036 - $7,306	-129 Reduced 25.39%	379 $21,000
Q4 2020 Feb 04, 2021	BUY	$27.07 - $84.35 $4,656 - $14,508	172 Added 51.19%	508 $36,000
Q4 2017 Feb 06, 2018	BUY	$21.89 - $31.34 $7,355 - $10,530	336	336 $10,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.